Christopher Evans
About Christopher Evans
Christopher Evans serves as the Vice President of Translational Sciences at Adaptimmune, where he contributes to clinical development strategy. He has extensive experience in regulatory affairs and has authored numerous scientific publications.
Work at Adaptimmune
Christopher Evans serves as the Vice President of Translational Sciences at Adaptimmune, a position he has held since 2020. In this role, he contributes to the clinical development strategy and execution as a member of the clinical development teams. His responsibilities include overseeing translational science initiatives that support the advancement of innovative therapies.
Education and Expertise
Christopher Evans earned a Bachelor of Science in Chemistry with Honors from the University of Maryland, studying from 1991 to 1995. He furthered his education at Purdue University, where he obtained a Doctor of Philosophy in Chemistry, specializing in Analytical Chemistry, from 1996 to 2001. His academic background provides a strong foundation for his extensive experience in regulatory affairs and biomarker assay development.
Background
Before joining Adaptimmune, Christopher Evans held various positions in the pharmaceutical and biotechnology sectors. He worked as an Associate Analyst in the Ion Beam Analysis Group at EAG Laboratories for seven months in 1996. He then spent 19 years at GSK, where he served as Senior Director and Head of US Bioanalysis and Biomarkers. Additionally, he was a Scientific Advisory Board member at AIT Bioscience from 2016 to 2019.
Achievements
Christopher Evans has authored four book chapters and 64 peer-reviewed manuscripts, making significant contributions to the scientific literature in his field. He formed and led a biomarker assay delivery group from 2015 to 2019, focusing on hypothesis-driven biomarker endpoints such as target engagement and receptor occupancy. He has also delivered nearly 70 oral presentations and facilitated conference sessions at both national and international conferences.